JP2008007411A - Transglutaminase production promoter and epidermal keratinization-normalizing agent - Google Patents
Transglutaminase production promoter and epidermal keratinization-normalizing agent Download PDFInfo
- Publication number
- JP2008007411A JP2008007411A JP2006176085A JP2006176085A JP2008007411A JP 2008007411 A JP2008007411 A JP 2008007411A JP 2006176085 A JP2006176085 A JP 2006176085A JP 2006176085 A JP2006176085 A JP 2006176085A JP 2008007411 A JP2008007411 A JP 2008007411A
- Authority
- JP
- Japan
- Prior art keywords
- transglutaminase
- extract
- transglutaminase production
- skin
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 40
- 108060008539 Transglutaminase Proteins 0.000 title abstract description 41
- 102000003601 transglutaminase Human genes 0.000 title abstract description 41
- 235000017309 Hypericum perforatum Nutrition 0.000 claims abstract description 12
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 11
- 235000009814 Luffa aegyptiaca Nutrition 0.000 claims abstract description 11
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 9
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 9
- 244000178231 Rosmarinus officinalis Species 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 241000555678 Citrus unshiu Species 0.000 claims abstract description 5
- 241000546188 Hypericum Species 0.000 claims description 11
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 9
- 235000003373 curcuma longa Nutrition 0.000 claims description 9
- 235000013976 turmeric Nutrition 0.000 claims description 9
- 240000000249 Morus alba Species 0.000 claims description 8
- 235000008708 Morus alba Nutrition 0.000 claims description 8
- 239000000419 plant extract Substances 0.000 claims description 7
- 241000222336 Ganoderma Species 0.000 claims 1
- 102000009127 Glutaminase Human genes 0.000 claims 1
- 108010073324 Glutaminase Proteins 0.000 claims 1
- 244000280244 Luffa acutangula Species 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 36
- 241000196324 Embryophyta Species 0.000 abstract description 17
- 230000001737 promoting effect Effects 0.000 abstract description 12
- 244000302544 Luffa aegyptiaca Species 0.000 abstract description 10
- 244000165082 Lavanda vera Species 0.000 abstract description 8
- 239000001102 lavandula vera Substances 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 210000002615 epidermis Anatomy 0.000 abstract description 4
- 240000008397 Ganoderma lucidum Species 0.000 abstract description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 3
- 235000010701 Lavanda vera Nutrition 0.000 abstract description 2
- 244000293610 Morus bombycis Species 0.000 abstract description 2
- 235000006721 Morus bombycis Nutrition 0.000 abstract description 2
- 239000001417 melissa officinalis l. Substances 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 235000015639 rosmarinus officinalis Nutrition 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 241000195950 Equisetum arvense Species 0.000 abstract 1
- 239000005768 Equisetum arvense L. Substances 0.000 abstract 1
- 241000782597 Hypericum erectum Species 0.000 abstract 1
- 244000141009 Hypericum perforatum Species 0.000 abstract 1
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 238000000605 extraction Methods 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 235000013399 edible fruits Nutrition 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 19
- 239000000203 mixture Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 10
- 230000003780 keratinization Effects 0.000 description 9
- 210000000434 stratum corneum Anatomy 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 244000025254 Cannabis sativa Species 0.000 description 7
- 244000062730 Melissa officinalis Species 0.000 description 7
- 244000183278 Nephelium litchi Species 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 7
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 6
- 235000018219 lavender Nutrition 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- 241000195955 Equisetum hyemale Species 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 230000037336 dry skin Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000012264 purified product Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000218645 Cedrus Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000207923 Lamiaceae Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- -1 and the like Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 102000007236 involucrin Human genes 0.000 description 2
- 108010033564 involucrin Proteins 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 239000012695 Ce precursor Substances 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000195952 Equisetaceae Species 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 102100031784 Loricrin Human genes 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- 235000015742 Nephelium litchi Nutrition 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 229940126902 Phlorizin Drugs 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 102100030944 Protein-glutamine gamma-glutamyltransferase K Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940083980 lavender extract Drugs 0.000 description 1
- 235000020723 lavender extract Nutrition 0.000 description 1
- 108010079309 loricrin Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 1
- IOUVKUPGCMBWBT-GHRYLNIYSA-N phlorizin Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 description 1
- 235000019139 phlorizin Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 239000001331 rosmarinus officinalis leaf Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000008417 skin turnover Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 108010058734 transglutaminase 1 Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、植物からの抽出物を有効成分とするトランスグルタミナーゼ産生促進剤及び
表皮角化正常化剤に関する。
The present invention relates to a transglutaminase production promoter and an epidermal keratinization normalizing agent comprising an extract from a plant as an active ingredient.
皮膚は、外界からの刺激、例えば、乾燥、紫外線、その他の物理的、化学的刺激を緩和したり、水分等の体内成分の喪失を防御する機能を有している。この重要な機能は、皮膚のバリア機能と呼ばれ、その機能維持に重要な役割を担っているのが角層である。
角層は、表皮角化細胞が終末分化して形成された角質細胞と、細胞間を埋める細胞間脂質から形成される。セラミドを主成分とする細胞間脂質は、ラメラ構造を形成することにより、角層バリア機能を担っている。一方、角質細胞は、ケラチン線維を主成分とし、膜の裏打ち蛋白であるコーニファイドエンベロープ(角質肥厚膜、以下「CE」と略)という疎水的で強靭な細胞膜様構造物に覆われている。CEは、表皮角化細胞の分化に従って細胞内で産生されるインボルクリン、ロリクリンなど複数のCE前駆体蛋白質が、酵素トランスグルタミナーゼにより架橋され不溶化して形成され、このCEが皮膚のバリア機能に密接に関与している。さらに、その一部にはセラミド等が共有結合し、疎水的な構造をとることで細胞間脂質のラメラ構造の土台を供給し、角層バリア機能及び皮膚の水分保持機能の基礎が形成される。
The skin has a function of mitigating external stimuli such as dryness, ultraviolet rays, and other physical and chemical stimuli, and protecting the loss of body components such as moisture. This important function is called a skin barrier function, and the stratum corneum plays an important role in maintaining the function.
The stratum corneum is formed from keratinocytes formed by terminal differentiation of epidermal keratinocytes and intercellular lipids that fill the space between the cells. Intercellular lipids mainly composed of ceramide have a stratum corneum barrier function by forming a lamellar structure. On the other hand, keratinocytes are mainly composed of keratin fibers and covered with a hydrophobic and strong cell membrane-like structure called a cornified envelope (keratin thickened membrane, hereinafter abbreviated as “CE”) which is a membrane lining protein. CE is formed by cross-linking and insolubilizing a plurality of CE precursor proteins such as involucrin and loricrin produced in the cells according to the differentiation of epidermal keratinocytes, and this CE is closely related to the barrier function of the skin. Is involved. Furthermore, ceramide and the like are covalently bonded to some of them, and the base of the lamellar structure of the intercellular lipid is supplied by taking a hydrophobic structure, and the basis of the stratum corneum barrier function and the moisture retention function of the skin is formed. .
角質細胞は、表皮角化細胞の分化(角化)によって次々と新しく作られ、古くなった角質細胞は垢として角層から脱落していく。これが、皮膚のターンオーバーと言われる現象である。ターンオーバーのサイクルは、正常な皮膚では約4週間と言われているが、加齢、乾燥、紫外線などの影響によりターンオーバー速度に異常が生じると、ラメラ構造の乱れやCEが不完全な状態で形成された、いわゆる不全角化が誘発され、角質細胞や細胞間脂質の構造に異常が生じ角層の水分保持機能およびバリア機能は低下する。このことが肌荒れ、乾燥肌等の皮膚の老化症状につながると考えられる。また、乾癬やアトピー性皮膚炎の患者では、バリア機能が低下した皮疹部で未熟なCEが高頻度に観察され、CEが正しく形成されることが皮膚のバリア機能に非常に重要であると考えられている(非特許文献1)。 The keratinocytes are newly created one after another by the differentiation (keratinization) of the epidermal keratinocytes, and the old keratinocytes fall off from the stratum corneum as plaque. This is a phenomenon called skin turnover. It is said that the turnover cycle is about 4 weeks for normal skin, but if the turnover speed becomes abnormal due to the effects of aging, drying, ultraviolet rays, etc., the lamella structure is disturbed and CE is incomplete. In other words, the so-called aberrant keratinization is induced, the structure of corneocytes and intercellular lipids is abnormal, and the water retention function and barrier function of the stratum corneum are reduced. This is thought to lead to skin aging symptoms such as rough skin and dry skin. In patients with psoriasis and atopic dermatitis, immature CE is frequently observed in the skin area where the barrier function is reduced, and the correct formation of CE is very important for the barrier function of the skin. (Non-Patent Document 1).
即ち、表皮においてトランスグルタミナーゼやインボルクリンの産生を促進することにより角質細胞の角化を促進し、健全な角層の形成を促すことによって、皮膚のバリア機能および水分保持機能を高め、乾燥肌、荒れ肌、アトピー性皮膚炎、乾癬などの皮膚症状を予防又は改善することができると考えられる。このような考えに基づき、トランスグルタミナーゼ産生促進作用を有するものとして、湖南甜茶抽出物とその酸加水分解物(特許文献1)、フロリジン及びフロレチン(特許文献2)、ビタミンD及びその関連化合物(特許文献3)、マツヨイグサ属植物の抽出物(特許文献4)等が知られている。
しかしながら、これまで角層バリア機能の低下に用いられていた成分は、細胞間脂質の成分を補うことや、皮膚に被膜を形成させることにより皮膚バリア機能の改善効果を発揮していたが、角質細胞のCEの構造については改善効果が十分でない場合もあり、健全なCEの形成に働きかける成分の開発が望まれていた。 However, the components that have been used to lower the stratum corneum barrier function so far have been effective in improving the skin barrier function by supplementing the components of intercellular lipids and forming a film on the skin. The improvement of the CE structure of the cells may not be sufficient, and it has been desired to develop a component that works to form a healthy CE.
そこで本発明においては、天然物の中から、表皮においてCE形成に不可欠な酵素トランスグルタミナーゼの産生促進作用を有する成分を見出し、これを有効成分として含有するトランスグルタミナーゼ産生促進剤並びに表皮角化正常化剤を提供することを目的とした。 Therefore, in the present invention, a component having an action of promoting the production of enzyme transglutaminase essential for CE formation in the epidermis is found from natural products, and a transglutaminase production promoter containing this as an active ingredient and normalization of epidermal keratinization The purpose was to provide an agent.
前記課題を解決するために、種々検討を行ったところ、スギナ、ヘチマ、ダイダイ、ボタン、ウンシュウミカン、オトギリソウ、クワ、ウコン、メリッサ、ラベンダー、レイシ及びローズマリーから選ばれる1種又は2種以上の植物抽出物にトランスグルタミナーゼ産生促進作用を見出し、本発明を完成するに至った。 In order to solve the above-mentioned problems, various studies have been conducted. As a result, one or more kinds selected from Sugina, Loofah, Daidai, Button, Satsumikan, Hypericum, Mulberry, Turmeric, Melissa, Lavender, Reishi and Rosemary are selected. A plant extract was found to promote transglutaminase production, and the present invention was completed.
本発明によると、スギナ、ヘチマ、ダイダイ、ボタン、ウンシュウミカン、オトギリソウ、クワ、ウコン、メリッサ、ラベンダー、レイシ及びローズマリーから選ばれる1種又は2種以上の植物抽出物を含有してなるトランスグルタミナーゼ産生促進剤が、優れた表皮トランスグルタミナーゼ産生促進作用を有し、表皮角質細胞の正常化による乾燥肌、荒れ肌、アトピー性皮膚炎、乾癬などの皮膚症状の予防・改善を効果的に行うことができる。 According to the present invention, transglutaminase containing one or more plant extracts selected from cedar, loofah, daidai, button, shrimp, hypericum, mulberry, turmeric, melissa, lavender, litchi and rosemary. The production promoter has an excellent epidermal transglutaminase production promoting effect, and can effectively prevent and improve skin symptoms such as dry skin, rough skin, atopic dermatitis, psoriasis due to normalization of epidermal keratinocytes it can.
本発明のトランスグルタミナーゼ産生促進剤は、スギナ、ヘチマ、ダイダイ、ボタン、ウンシュウミカン、オトギリソウ、クワ、ウコン、メリッサ、ラベンダー、レイシ及びローズマリーから選ばれる1種又は2種以上の植物抽出物を含有してなり、さらに必要に応じてその他の成分を含有してなる。 The transglutaminase production promoter of the present invention contains one or more plant extracts selected from cedar, loofah, daidai, button, mandarin orange, hypericum, mulberry, turmeric, melissa, lavender, litchi and rosemary. In addition, it contains other components as required.
前記スギナは、トクサ科(Equisetaceae)の植物であり、学名はEquisetum arvense L.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、特に全草が好ましい。 The horsetail is a plant belonging to the family Equisetaceae, and its scientific name is Equisetum arvense L. et al. It is. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, Especially the whole plant is preferable.
前記ヘチマは、ウリ科(Cucurbitaceae)の植物であり、学名はLuffa cylindrica M.Roemenである。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、蕾、果実、果皮、果核、地上部またはこれらの混合物が挙げられる。これらの中でも特に地上部を用いることが好ましい。 The loofah is a plant of the Cucurbitaceae family, and its scientific name is Luffa cylindrica M. et al. Roemen. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a bud, a fruit, a fruit skin, a fruit core, an above-ground part, or these mixtures are mentioned. Among these, it is particularly preferable to use the above-ground part.
前記ダイダイは、ミカン科(Rutaceae)の植物であり、学名はCitrus aurantium L.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、蕾、果実、果皮、果核、地上部、全草またはこれらの混合物が挙げられる。これらの中でも特に果皮が好ましい。 The Daidai is a plant of the Rutaceae family, and its scientific name is Citrus aurantium L. It is. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a bud, a fruit, a fruit skin, a fruit core, an above-ground part, whole grass, or these mixtures are mentioned. Of these, the peel is particularly preferred.
前記ボタンは、ボタン科(Paeoniaceae)の植物であり、学名はPaeonia suffruticosa Andrewsである。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、根、根皮、地上部またはこれらの混合物が挙げられる。これらの中でも特に根皮を用いることが好ましい。 The button is a plant of the Paeoniaceae family and the scientific name is Paeonia suffrificosa Andrews. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a root, a root bark, an above-ground part, or these mixtures are mentioned. Of these, root bark is particularly preferred.
前記ウンシュウミカンは、ミカン科(Rutaceae)の植物であり、学名はCitrus unshiu Markovichである。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、枝、花、蕾、果実、果皮、果核、地上部、全草またはこれらの混合物が挙げられる。これらの中でも特に果皮を用いることが好ましい。 The Citrus unshiu is a plant belonging to the family Rutaceae, and its scientific name is Citrus unshiu Markovich. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a branch, a flower, a cocoon, a fruit, a fruit skin, a fruit core, an above-ground part, whole grass, or a mixture thereof is mentioned. Among these, it is particularly preferable to use a peel.
前記オトギリソウは、オトギリソウ科(Guttiferae)の植物であり、学名はHypericum erectum Thunb.またはHypericum perforatum L.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、根、花、地上部、全草またはこれらの混合物が挙げられる。これらの中でも地上部又は全草を用いることが好ましい。 The hypericum is a plant of the family Glutiferae, and its scientific name is Hypericum electum Thumb. Or Hypericum performancea L. It is. There is no restriction | limiting in particular in a structural part, According to the objective, it can select suitably, For example, a leaf, a stem, a root, a flower, an above-ground part, whole grass, or a mixture thereof is mentioned. Among these, it is preferable to use the above-ground part or whole grass.
前記クワは、クワ科(Moraceae)の植物であり、学名はMorus bombycis Koidzumiである。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、根、根皮、地上部またはこれらの混合物が挙げられる。これらの中でも特に根皮を用いることが好ましい。 The mulberry is a plant belonging to the family Moraceae, and its scientific name is Morus bombycis Koidzumi. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a root, a root bark, an above-ground part, or these mixtures are mentioned. Of these, root bark is particularly preferred.
前記ウコンは、ショウガ科(Zingiberaceae)の植物であり、学名はCurcuma longa L.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、蕾、根茎、地上部またはこれらの混合物が挙げられる。これらの中でも特に根茎を用いることが好ましい。 The turmeric is a plant belonging to the family Zingiberaceae and has a scientific name of Curcuma longa L. It is. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a bud, a rhizome, an above-ground part, or these mixtures are mentioned. Among these, it is particularly preferable to use a rhizome.
前記メリッサは、シソ科(Labiatae)の植物であり、学名はMelissa officinalis L.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、根、花、果実、果皮、果核、全草またはこれらの混合物が挙げられる。これらの中でも特に葉を用いることが好ましい。 The Melissa is a plant of the Labiatae family and has a scientific name of Melissa officinalis L. It is. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a root, a flower, a fruit, a fruit peel, a fruit nucleus, whole grass, or a mixture thereof is mentioned. Among these, it is particularly preferable to use leaves.
前記ラベンダーは、シソ科(Labiatae)の植物であり、学名はLavandula vera D.C.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、根、果実、果皮、果核またはこれらの混合物が挙げられる。これらの中でも特に花を用いることが好ましい。 The lavender is a plant belonging to the family Labiatae, and the scientific name is Lavandula vera D. et al. C. It is. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a root, a fruit, a fruit skin, a fruit nucleus, or a mixture thereof is mentioned. Among these, it is particularly preferable to use flowers.
前記レイシは、サルノコシカケ科(Polyporaceae)の植物であり、学名はGanoderma lucidum(Fr.)Karst.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、特に子実体を用いることが好ましい。 The litchi is a plant of the Polypoaceae family, and has a scientific name of Ganoderma lucidum (Fr.) Karst. It is. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, It is preferable to use a fruit body especially.
前記ローズマリーは、シソ科(Labiatae)の植物であり、学名はRosmarinus officinalis L.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、蕾、果実、果皮、果核、地上部、全草またはこれらの混合物が挙げられる。これらの中でも特に葉を用いることが好ましい。 The rosemary is a plant of the Labiatae family and has a scientific name of Rosmarinus officinalis L. It is. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a bud, a fruit, a fruit skin, a fruit core, an above-ground part, whole grass, or these mixtures are mentioned. Among these, it is particularly preferable to use leaves.
なお、前記スギナ、ヘチマ、ダイダイ、ボタン、ウンシュウミカン、オトギリソウ、クワ、ウコン、メリッサ、ラベンダー、レイシ及びローズマリーから選ばれる1種又は2種以上の植物抽出物が含有する有効成分であるトランスグルタミナーゼ産生促進作用物質の詳細については不明であるが、これらの有効成分は植物の抽出に一般に用いられている方法により抽出したものを使用してもよいし、市販品を使用してもよい。前記抽出物には、抽出処理によって抽出原料から得られる抽出液、該抽出液の希釈液もしくは濃縮液、該抽出液を乾燥して得られる乾燥物、又はこれらの粗精製物もしくは精製物のいずれもが含まれる。 In addition, transglutaminase which is an active ingredient contained in one or more plant extracts selected from the above cedar, loofah, daidai, button, unshimikan, hypericum, mulberry, turmeric, melissa, lavender, litchi and rosemary Although details of the production promoting substance are unknown, those active ingredients may be extracted by a method generally used for plant extraction, or commercially available products may be used. The extract includes any one of an extract obtained from an extraction raw material by an extraction process, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, or a roughly purified product or a purified product thereof. Is also included.
前記抽出原料は、採取後ただちに乾燥し粉砕したものが適当である。乾燥は天日で行ってもよいし、通常使用される乾燥機を用いて行ってもよい。また、ヘキサン、ベンゼン等の非極性溶媒によって脱脂等の前処理を施してから抽出原料として使用してもよい。 The extraction raw material is suitably dried and pulverized immediately after collection. Drying may be performed in the sun or using a commonly used dryer. Moreover, after performing pre-processing, such as degreasing, with nonpolar solvents, such as hexane and benzene, you may use as an extraction raw material.
前記抽出に用いる溶媒としては、水若しくは親水性有機溶媒又はこれらの混合液を室温又は溶媒の沸点以下の温度で用いることが好ましい。各植物に含まれるトランスグルタミナーゼ産生促進作用を示す成分は、極性溶媒を抽出溶媒とする抽出処理によって容易に抽出することができる。 As the solvent used for the extraction, it is preferable to use water, a hydrophilic organic solvent, or a mixture thereof at room temperature or a temperature not higher than the boiling point of the solvent. A component showing the transglutaminase production promoting action contained in each plant can be easily extracted by an extraction treatment using a polar solvent as an extraction solvent.
前記抽出溶媒として使用し得る水としては、例えば、純水、水道水、井戸水、鉱泉水、鉱水、温泉水、湧水、淡水等の他、これらに各種処理を施したものが含まれる。水に施す処理としては、例えば、精製、加熱、殺菌、ろ過、イオン交換、浸透圧の調整、緩衝化等が含まれる。従って、本発明において抽出溶媒として使用し得る水には、精製水、熱水、イオン交換水、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等も含まれる。 Examples of water that can be used as the extraction solvent include pure water, tap water, well water, mineral spring water, mineral water, hot spring water, spring water, fresh water, and the like, as well as water that has been subjected to various treatments. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, adjustment of osmotic pressure, buffering, and the like. Therefore, the water that can be used as the extraction solvent in the present invention includes purified water, hot water, ion-exchanged water, physiological saline, phosphate buffer, phosphate buffered saline, and the like.
前記親水性有機溶媒としては、例えば、メタノール、エタノール、プロピルアルコール、イソプロピルアルコール等の炭素数1〜5の低級アルコール;アセトン、メチルエチルケトン等の低級脂肪族ケトン;1,3−ブチレングリコール、プロピレングリコール、グリセリン等の炭素数2〜5の多価アルコールなどが挙げられ、該親水性有機溶媒と水との混合溶媒などを用いることができる。 Examples of the hydrophilic organic solvent include lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; 1,3-butylene glycol, propylene glycol, Examples thereof include polyhydric alcohols having 2 to 5 carbon atoms such as glycerin, and a mixed solvent of the hydrophilic organic solvent and water can be used.
なお、前記水と親水性有機溶媒との抽出溶媒を使用する場合には、低級アルコールの場合は水10質量部に対して1〜90質量部、低級脂肪族ケトンの場合は水10質量部に対して1〜40質量部添加することが好ましい。多価アルコールの場合は水10質量部に対して1〜90質量部添加することが好ましい。 In addition, when using the extraction solvent of the said water and a hydrophilic organic solvent, in the case of a lower alcohol, it is 1-90 mass parts with respect to 10 mass parts of water, and in the case of a lower aliphatic ketone, it is 10 mass parts of water. It is preferable to add 1-40 mass parts with respect to it. In the case of a polyhydric alcohol, it is preferable to add 1 to 90 parts by mass with respect to 10 parts by mass of water.
本発明において、前記各抽出原料からトランスグルタミナーゼ産生促進物質を抽出するにあたって特殊な抽出方法を採用する必要はなく、室温又は還流加熱下で、任意の装置を用いて抽出することができる。 In the present invention, it is not necessary to employ a special extraction method for extracting the transglutaminase production promoting substance from each extraction raw material, and the extraction can be performed using an arbitrary apparatus at room temperature or under reflux heating.
具体的には、抽出溶媒を満たした処理槽に各抽出原料を投入し、更に必要に応じて時々攪拌しながら、30分〜4時間静置して可溶性成分を溶出した後、ろ過して固形物を除去し、得られた抽出液から抽出溶媒を留去し、乾燥することにより抽出物が得られる。抽出溶媒量は通常、抽出原料の5〜15倍量(質量比)である。抽出条件は、抽出溶媒として水を用いた場合には、通常50〜95℃で1〜4時間程度である。また、抽出溶媒として水とエタノールとの混合溶媒を用いた場合には、通常40〜80℃で30分〜4時間程度である。なお、溶媒で抽出することにより得られる抽出液は、抽出溶媒が安全性の高いものであればそのまま配合して本発明のトランスグルタミナーゼ産生促進剤及び/又は表皮角化正常化剤の有効成分として使用することができるが、濃縮液又はその乾燥物としたものの方が利用しやすい。 Specifically, each extraction raw material is put into a treatment tank filled with an extraction solvent, and further, while stirring occasionally as necessary, the mixture is allowed to stand for 30 minutes to 4 hours to elute soluble components, and then filtered and solidified. An extract is obtained by removing a thing, distilling an extraction solvent off from the obtained extract, and drying. The amount of the extraction solvent is usually 5 to 15 times (mass ratio) of the extraction raw material. The extraction condition is usually about 1 to 4 hours at 50 to 95 ° C. when water is used as the extraction solvent. Moreover, when using the mixed solvent of water and ethanol as an extraction solvent, it is about 30 minutes-4 hours at 40-80 degreeC normally. In addition, the extract obtained by extracting with a solvent, if the extraction solvent is highly safe, is blended as it is as an active ingredient of the transglutaminase production promoter and / or epidermal keratinization normalizing agent of the present invention. Although it can be used, it is easier to use a concentrated solution or a dried product thereof.
得られた抽出液は、該抽出液の希釈液若しくは濃縮液、該抽出液の乾燥物、又はこれらの粗精製物若しくは精製物を得るために、常法に従って希釈、濃縮、乾燥、精製等の処理を施してもよい。 The obtained extract is diluted, concentrated, dried, purified, etc. according to a conventional method in order to obtain a diluted or concentrated solution of the extract, a dried product of the extract, or a crude purified product or a purified product thereof. Processing may be performed.
なお、得られた抽出液はそのままでもトランスグルタミナーゼ産生促進剤及び/又は表皮角化正常化剤として使用することができるが、濃縮液又はその乾燥物としたものの方が利用しやすい。乾燥物を得るにあたっては、吸湿性を改善するためにデキストリン、シクロデキストリン等のキャリアーを添加してもよい。 In addition, although the obtained extract can be used as it is as a transglutaminase production promoter and / or a skin keratinization normalizing agent, a concentrated solution or a dried product thereof is easier to use. In obtaining a dried product, a carrier such as dextrin or cyclodextrin may be added to improve hygroscopicity.
また、各抽出原料は特有の匂いと味を有しているため、その生理活性の低下を招かない範囲で脱色、脱臭等を目的とする精製を行うことも可能であるが、化粧料に添加する場合には大量に使用するものではないから、未精製のままでも実用上支障はない。精製は、具体的には活性炭処理、吸着樹脂処理、イオン交換樹脂処理等によって行うことができる。 In addition, since each extraction raw material has a unique odor and taste, it is possible to carry out purification for the purpose of decolorization, deodorization, etc. within a range that does not cause a decrease in its physiological activity, but it is added to cosmetics. In this case, since it is not used in large quantities, there is no practical problem even if it is not purified. Specifically, purification can be performed by activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, or the like.
本発明のトランスグルタミナーゼ産生促進剤及び/又は表皮角化正常化剤は、製剤化により粉末状、顆粒状、錠剤状等、任意の剤形とすることができる。 The transglutaminase production promoter and / or epidermal keratinization normalizing agent of the present invention can be made into any dosage form such as powder, granule, tablet, etc. by formulation.
以下、本発明の実施例を説明するが、本発明は、これらの実施例に何ら限定されるものではない。なお、本実施例で使用する、前記スギナ抽出液、ヘチマ抽出液−JC、トウヒ抽出液、ボタンピ抽出液、チンピ抽出液、オトギリソウ抽出液−J、ソウハクヒ抽出液、ウコン抽出液−J、メリッサ抽出液−J、ラベンダー抽出液、レイシ抽出液及びローズマリー抽出液(全て丸善製薬社製)の各凍結乾燥品を試料として用いた。 Examples of the present invention will be described below, but the present invention is not limited to these examples. In addition, the said horsetail extract, loofah extract-JC, spruce extract, button pi extract, chimpi extract, hypericum extract-J, Soraku extract, turmeric extract-J, Melissa extract used in this Example Each lyophilized product of liquid-J, lavender extract, litchi extract and rosemary extract (all manufactured by Maruzen Pharmaceutical Co., Ltd.) was used as a sample.
[試験例1]トランスグルタミナーゼ産生促進作用試験
上記の各抽出物について、下記の方法によりトランスグルタミナーゼ産生促進作用の試験をした。
[Test Example 1] Transglutaminase production promoting action test
Each of the above extracts was tested for the effect of promoting transglutaminase production by the following method.
正常ヒト皮膚表皮角化細胞(NHEK)を80cm2のフラスコで正常ヒト表皮角化細胞培地(KGM)にて37℃、5%CO2下で培養し、トリプシン処理により細胞を回収した。回収した細胞を1.0×105個/mLの細胞密度となるようにKGMで希釈した後、96ウェルプレートに1ウェルあたり100μLずつ播種し、5%CO2下、37℃で2日間培養した。 Normal human skin epidermal keratinocytes (NHEK) were cultured in normal human epidermal keratinocyte medium (KGM) at 37 ° C. and 5% CO 2 in an 80 cm 2 flask, and the cells were collected by trypsin treatment. The collected cells are diluted with KGM to a cell density of 1.0 × 10 5 cells / mL, then seeded at 100 μL per well in a 96-well plate, and cultured at 37 ° C. under 5% CO 2 for 2 days. did.
培養終了後、KGMで溶解した試料溶液を各ウェルに100μLずつ添加し、37℃、5%CO2下で24時間培養した。培養終了後、 培地を抜き、細胞をプレートに固定させ細胞表面に発現したトランスグルタミナーゼの量をモノクローナル抗ヒトトランスグルタミナーゼ-1抗体を用いたELISA法により測定した。得られた測定結果から、下記式によりトランスグルタミナーゼ産生促進率(%)を算出した。
トランスグルタミナーゼ産生促進率(%)=A / B × 100
式中、Aは「試料添加時の波長405nmにおける吸光度」を表し、Bは「試料無添加時の波長405nmにおける吸光度」を表す。
After completion of the culture, 100 μL of a sample solution dissolved in KGM was added to each well and cultured at 37 ° C. under 5% CO 2 for 24 hours. After completion of the culture, the medium was removed, the cells were fixed on a plate, and the amount of transglutaminase expressed on the cell surface was measured by ELISA using a monoclonal anti-human transglutaminase-1 antibody. From the obtained measurement results, the transglutaminase production promotion rate (%) was calculated by the following formula.
Transglutaminase production promotion rate (%) = A / B × 100
In the formula, A represents “absorbance at a wavelength of 405 nm when a sample is added”, and B represents “absorbance at a wavelength of 405 nm when no sample is added”.
上記試験の結果を表1〜12に示す。なお、上記計算式において、試料無添加のトランスグルタミナーゼ産生促進率は100%となる。 The result of the said test is shown to Tables 1-12. In the above calculation formula, the rate of acceleration of transglutaminase production without addition of the sample is 100%.
[表1]
スギナの全草抽出物の添加濃度 トランスグルタミナーゼ産生促進率
100.0μ g/mL 106.1%
25.0μ g/mL 114.1%
[Table 1]
Transglutaminase production promotion rate of added concentration of Japanese horsetail extracts
100.0 μg / mL 106.1%
25.0 μg / mL 114.1%
[表2]
ヘチマの地上部抽出物の添加濃度 トランスグルタミナーゼ産生促進率
50.0μ g/mL 104.8%
12.5μ g/mL 109.3%
[Table 2]
Transglutaminase production promotion rate of added concentration of aboveground extract of loofah
50.0 μg / mL 104.8%
12.5 μg / mL 109.3%
[表3]
ダイダイの果皮抽出物の添加濃度 トランスグルタミナーゼ産生促進率
50.0μ g/mL 114.8%
12.5μ g/mL 114.3%
[Table 3]
Daigluta pericarp extract concentration concentration transglutaminase production promotion rate
50.0 μg / mL 114.8%
12.5 μg / mL 114.3%
[表4]
ボタンの根皮抽出物の添加濃度 トランスグルタミナーゼ産生促進率
50.0μ g/mL 101.9%
12.5μ g/mL 117.0%
[Table 4]
Button root bark extract addition concentration transglutaminase production promotion rate
50.0 μg / mL 101.9%
12.5 μg / mL 117.0%
[表5]
ウンシュウミカンの果皮抽出物の添加濃度 トランスグルタミナーゼ産生促進率
50.0μ g/mL 116.8%
12.5μ g/mL 104.6%
[Table 5]
Transglutaminase production promotion rate of added concentration of Citrus unshiu peel extract
50.0 μg / mL 116.8%
12.5 μg / mL 104.6%
[表6]
オトギリソウの全草抽出物の添加濃度 トランスグルタミナーゼ産生促進率
50.0μ g/mL 112.4%
12.5μ g/mL 110.7%
[Table 6]
Transglutaminase production promotion rate of added concentration of hypericum whole grass extract
50.0 μg / mL 112.4%
12.5 μg / mL 110.7%
[表7]
クワの根皮抽出物の添加濃度 トランスグルタミナーゼ産生促進率
50.0μ g/mL 107.1%
12.5μ g/mL 107.4%
[Table 7]
Mulberry root bark extract added concentration transglutaminase production promotion rate
50.0 μg / mL 107.1%
12.5 μg / mL 107.4%
[表8]
ウコンの根茎抽出物の添加濃度 トランスグルタミナーゼ産生促進率
50.0μ g/mL 109.6%
12.5μ g/mL 118.9%
[Table 8]
Accelerated rate of transglutaminase production in turmeric rhizome extract
50.0 μg / mL 109.6%
12.5 μg / mL 118.9%
[表9]
メリッサの葉抽出物の添加濃度 トランスグルタミナーゼ産生促進率
50.0μ g/mL 104.0%
12.5μ g/mL 112.2%
[Table 9]
Melissa leaf extract added concentration transglutaminase production promotion rate
50.0 μg / mL 104.0%
12.5 μg / mL 112.2%
[表10]
ラベンダーの花抽出物の添加濃度 トランスグルタミナーゼ産生促進率
50.0μ g/mL 113.3%
12.5μ g/mL 107.2%
[Table 10]
Lavender flower extract added concentration transglutaminase production promotion rate
50.0 μg / mL 113.3%
12.5 μg / mL 107.2%
[表11]
レイシの子実体抽出物の添加濃度 トランスグルタミナーゼ産生促進率
50.0μ g/mL 112.2%
12.5μ g/mL 110.6%
[Table 11]
Transglutaminase production promotion rate of litchi fruiting body extract
50.0 μg / mL 112.2%
12.5 μg / mL 110.6%
[表12]
ローズマリーの葉抽出物の添加濃度 トランスグルタミナーゼ産生促進率
50.0μ g/mL 105.2%
12.5μ g/mL 114.8%
[Table 12]
Increased transglutaminase production rate of rosemary leaf extract
50.0 μg / mL 105.2%
12.5 μg / mL 114.8%
表1〜12に示すように、スギナ、ヘチマ、ダイダイ、ボタン、ウンシュウミカン、オトギリソウ、クワ、ウコン、メリッサ、ラベンダー、レイシ及びローズマリーから選ばれる1種又は2種以上の植物抽出物は、いずれも高いトランスグルタミナーゼ産生促進率を示した。この結果から、これらの抽出物は、優れたトランスグルタミナーゼ産生促進作用を有することが確認された。 As shown in Tables 1 to 12, one or two or more plant extracts selected from horsetail, loofah, daidai, button, mandarin orange, hypericum, mulberry, turmeric, melissa, lavender, lychee and rosemary, Also showed a high transglutaminase production promotion rate. From these results, it was confirmed that these extracts have an excellent transglutaminase production promoting action.
本発明のトランスグルタミナーゼ産生促進剤及び表皮角化正常化剤は、表皮におけるトランスグルタミナーゼの産生促進作用によって表皮角質細胞を正常化させることにより、乾燥肌、荒れ肌、アトピー性皮膚炎、乾癬などの皮膚症状の予防・改善に大きく貢献できる。 The transglutaminase production promoter and epidermal keratinization normalizing agent of the present invention normalizes epidermal keratinocytes by transglutaminase production promoting action in the epidermis, thereby causing skin such as dry skin, rough skin, atopic dermatitis, psoriasis, etc. Can greatly contribute to the prevention and improvement of symptoms.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006176085A JP2008007411A (en) | 2006-06-27 | 2006-06-27 | Transglutaminase production promoter and epidermal keratinization-normalizing agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006176085A JP2008007411A (en) | 2006-06-27 | 2006-06-27 | Transglutaminase production promoter and epidermal keratinization-normalizing agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008007411A true JP2008007411A (en) | 2008-01-17 |
Family
ID=39065933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006176085A Pending JP2008007411A (en) | 2006-06-27 | 2006-06-27 | Transglutaminase production promoter and epidermal keratinization-normalizing agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2008007411A (en) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009242310A (en) * | 2008-03-31 | 2009-10-22 | Kose Corp | Involucrin production promoter, transglutaminase-1 production promoter, e-cadherin production promoter and skin care preparation for external use for making skin pore inconspicuous |
| JP2010105925A (en) * | 2008-10-28 | 2010-05-13 | Juntendo | Skin keratinization-promoting agent |
| JP2011088845A (en) * | 2009-10-21 | 2011-05-06 | Kao Corp | Involucrin expression inhibitor |
| JP2011088854A (en) * | 2009-10-22 | 2011-05-06 | Kao Corp | Involucrin expression inhibitor |
| JP2012171949A (en) * | 2011-02-24 | 2012-09-10 | Nagase & Co Ltd | Expression enhancer of melatonin receptor and method for producing the same |
| CN102716393A (en) * | 2012-06-13 | 2012-10-10 | 陈和平 | Externally applied traditional Chinese medicine for treating dermatomycosis and bromhidrosis and preparation method of traditional Chinese medicine |
| US20140010901A1 (en) * | 2011-03-15 | 2014-01-09 | Shiseido Company, Ltd. | Bleomycin hydrolase production promotor |
| JP2014091729A (en) * | 2012-11-06 | 2014-05-19 | Fancl Corp | Mif secretion inhibitor |
| JP2014091727A (en) * | 2012-11-06 | 2014-05-19 | Fancl Corp | Mif secretion inhibitor |
| KR20170025361A (en) * | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| JP2017066106A (en) * | 2015-09-30 | 2017-04-06 | 小林製薬株式会社 | Sebum secretion promoter and use thereof |
| JP2017075117A (en) * | 2015-10-14 | 2017-04-20 | 丸善製薬株式会社 | Barrier function improver |
| KR20180041107A (en) * | 2018-04-16 | 2018-04-23 | 주식회사 엘지생활건강 | Composition for improving skin |
| CN107982101A (en) * | 2017-11-09 | 2018-05-04 | 恩馨(北京)生物科技有限公司 | A kind of natural reparative factor, the preparation method and use of effectively reparative regeneration |
| JP2018127407A (en) * | 2017-02-07 | 2018-08-16 | 日華化学株式会社 | Epidermis normalizing agent and external preparation and cosmetic containing the same |
| US10071042B2 (en) | 2014-04-14 | 2018-09-11 | Hayashibara Co., Ltd. | External dermatological agent for anti-ageing |
| JP2019081712A (en) * | 2017-10-27 | 2019-05-30 | 丸善製薬株式会社 | Nerve growth factor expression inhibitor and semaphorin 3A expression promoter |
| JP2022161273A (en) * | 2021-04-08 | 2022-10-21 | 丸善製薬株式会社 | Epidermal keratinocyte growth stimulator and transglutaminase-1 mrna expression promoter |
| JP2023075558A (en) * | 2021-11-19 | 2023-05-31 | 日本メナード化粧品株式会社 | Transglutaminase I production promoter and involucrin production promoter |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58113118A (en) * | 1981-12-26 | 1983-07-05 | Nonogawa Shoji:Kk | Cosmetic |
| JPS6253911A (en) * | 1985-09-02 | 1987-03-09 | Shiseido Co Ltd | Cosmetic |
| JPS6483013A (en) * | 1987-09-24 | 1989-03-28 | Narisu Cosmetic Co Ltd | Dermal drug for external use |
| JPH02184613A (en) * | 1989-01-09 | 1990-07-19 | Nonogawa Shoji:Kk | Skin cosmetic |
| JPH04305512A (en) * | 1991-03-29 | 1992-10-28 | Shiseido Co Ltd | External preparation for skin |
| JPH0820522A (en) * | 1994-07-07 | 1996-01-23 | Pola Chem Ind Inc | Keratinizing anzyme activity promoter and cosmetic containing the same |
| JPH1129460A (en) * | 1997-07-04 | 1999-02-02 | Pola Chem Ind Inc | Cosmetic for sensitive skin |
| JPH1160496A (en) * | 1997-08-13 | 1999-03-02 | Advanced Sukin Res Kenkyusho:Kk | Hyaluronic acid production enhancer |
| JP2000169383A (en) * | 1998-12-07 | 2000-06-20 | Ichimaru Pharcos Co Ltd | Antiallergic agent |
| JP2003171310A (en) * | 2002-05-02 | 2003-06-20 | Noevir Co Ltd | Skin barrier function-reinforcing agent |
| JP2003292432A (en) * | 2002-04-04 | 2003-10-15 | Noevir Co Ltd | Skin care preparation |
| JP2004091376A (en) * | 2002-08-30 | 2004-03-25 | Naris Cosmetics Co Ltd | Epidermis keratinization normalizing agent and skin care preparation for external use for skin containing the same |
| JP2005213178A (en) * | 2004-01-29 | 2005-08-11 | Maruzen Pharmaceut Co Ltd | TNF-alpha PRODUCTION INHIBITOR, ESTROGENIC AGENT AND EXTERNAL PREPARATION FOR SKIN |
| JP2006056902A (en) * | 2005-10-24 | 2006-03-02 | Shiseido Co Ltd | Medicament for pruritus, chapped skin, sensitive skin and whitening by suppressing production/release of stem cell factor |
| JP2007174931A (en) * | 2005-12-27 | 2007-07-12 | Pola Chem Ind Inc | Epidermal keratinocyte layer membrane and utilization of the epidermal keratinocyte layer membrane |
| JP2007176835A (en) * | 2005-12-27 | 2007-07-12 | Pola Chem Ind Inc | External preparation for skin, for improving skin barrier function and its production method |
| JP2008007412A (en) * | 2006-06-27 | 2008-01-17 | Maruzen Pharmaceut Co Ltd | Involucrin production promoter and epidermal keratinization-normalizing agent |
-
2006
- 2006-06-27 JP JP2006176085A patent/JP2008007411A/en active Pending
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58113118A (en) * | 1981-12-26 | 1983-07-05 | Nonogawa Shoji:Kk | Cosmetic |
| JPS6253911A (en) * | 1985-09-02 | 1987-03-09 | Shiseido Co Ltd | Cosmetic |
| JPS6483013A (en) * | 1987-09-24 | 1989-03-28 | Narisu Cosmetic Co Ltd | Dermal drug for external use |
| JPH02184613A (en) * | 1989-01-09 | 1990-07-19 | Nonogawa Shoji:Kk | Skin cosmetic |
| JPH04305512A (en) * | 1991-03-29 | 1992-10-28 | Shiseido Co Ltd | External preparation for skin |
| JPH0820522A (en) * | 1994-07-07 | 1996-01-23 | Pola Chem Ind Inc | Keratinizing anzyme activity promoter and cosmetic containing the same |
| JPH1129460A (en) * | 1997-07-04 | 1999-02-02 | Pola Chem Ind Inc | Cosmetic for sensitive skin |
| JPH1160496A (en) * | 1997-08-13 | 1999-03-02 | Advanced Sukin Res Kenkyusho:Kk | Hyaluronic acid production enhancer |
| JP2000169383A (en) * | 1998-12-07 | 2000-06-20 | Ichimaru Pharcos Co Ltd | Antiallergic agent |
| JP2003292432A (en) * | 2002-04-04 | 2003-10-15 | Noevir Co Ltd | Skin care preparation |
| JP2003171310A (en) * | 2002-05-02 | 2003-06-20 | Noevir Co Ltd | Skin barrier function-reinforcing agent |
| JP2004091376A (en) * | 2002-08-30 | 2004-03-25 | Naris Cosmetics Co Ltd | Epidermis keratinization normalizing agent and skin care preparation for external use for skin containing the same |
| JP2005213178A (en) * | 2004-01-29 | 2005-08-11 | Maruzen Pharmaceut Co Ltd | TNF-alpha PRODUCTION INHIBITOR, ESTROGENIC AGENT AND EXTERNAL PREPARATION FOR SKIN |
| JP2006056902A (en) * | 2005-10-24 | 2006-03-02 | Shiseido Co Ltd | Medicament for pruritus, chapped skin, sensitive skin and whitening by suppressing production/release of stem cell factor |
| JP2007174931A (en) * | 2005-12-27 | 2007-07-12 | Pola Chem Ind Inc | Epidermal keratinocyte layer membrane and utilization of the epidermal keratinocyte layer membrane |
| JP2007176835A (en) * | 2005-12-27 | 2007-07-12 | Pola Chem Ind Inc | External preparation for skin, for improving skin barrier function and its production method |
| JP2008007412A (en) * | 2006-06-27 | 2008-01-17 | Maruzen Pharmaceut Co Ltd | Involucrin production promoter and epidermal keratinization-normalizing agent |
Non-Patent Citations (3)
| Title |
|---|
| CSNC200801365022; Fragr. J. Vol.31 No.2, pp.84-93, ▲C▼フレグランス ジャーナル社 * |
| JPN6012013201; Fragr. J. Vol.31 No.2, pp.84-93, ▲C▼フレグランス ジャーナル社 * |
| JPN6012039743; Ear Res. Jpn. Vol.18, 1987, pp.314-317 * |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009242310A (en) * | 2008-03-31 | 2009-10-22 | Kose Corp | Involucrin production promoter, transglutaminase-1 production promoter, e-cadherin production promoter and skin care preparation for external use for making skin pore inconspicuous |
| JP2010105925A (en) * | 2008-10-28 | 2010-05-13 | Juntendo | Skin keratinization-promoting agent |
| JP2011088845A (en) * | 2009-10-21 | 2011-05-06 | Kao Corp | Involucrin expression inhibitor |
| JP2011088854A (en) * | 2009-10-22 | 2011-05-06 | Kao Corp | Involucrin expression inhibitor |
| JP2012171949A (en) * | 2011-02-24 | 2012-09-10 | Nagase & Co Ltd | Expression enhancer of melatonin receptor and method for producing the same |
| US20140010901A1 (en) * | 2011-03-15 | 2014-01-09 | Shiseido Company, Ltd. | Bleomycin hydrolase production promotor |
| CN102716393A (en) * | 2012-06-13 | 2012-10-10 | 陈和平 | Externally applied traditional Chinese medicine for treating dermatomycosis and bromhidrosis and preparation method of traditional Chinese medicine |
| JP2014091729A (en) * | 2012-11-06 | 2014-05-19 | Fancl Corp | Mif secretion inhibitor |
| JP2014091727A (en) * | 2012-11-06 | 2014-05-19 | Fancl Corp | Mif secretion inhibitor |
| US10071042B2 (en) | 2014-04-14 | 2018-09-11 | Hayashibara Co., Ltd. | External dermatological agent for anti-ageing |
| KR101872919B1 (en) * | 2015-08-28 | 2018-06-29 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR20170025361A (en) * | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
| WO2017057420A1 (en) * | 2015-09-30 | 2017-04-06 | 小林製薬株式会社 | Sebum secretion promoter and utilization thereof |
| JP2017066106A (en) * | 2015-09-30 | 2017-04-06 | 小林製薬株式会社 | Sebum secretion promoter and use thereof |
| JP2017075117A (en) * | 2015-10-14 | 2017-04-20 | 丸善製薬株式会社 | Barrier function improver |
| JP2018127407A (en) * | 2017-02-07 | 2018-08-16 | 日華化学株式会社 | Epidermis normalizing agent and external preparation and cosmetic containing the same |
| JP2019081712A (en) * | 2017-10-27 | 2019-05-30 | 丸善製薬株式会社 | Nerve growth factor expression inhibitor and semaphorin 3A expression promoter |
| CN107982101A (en) * | 2017-11-09 | 2018-05-04 | 恩馨(北京)生物科技有限公司 | A kind of natural reparative factor, the preparation method and use of effectively reparative regeneration |
| CN107982101B (en) * | 2017-11-09 | 2020-10-09 | 恩馨(北京)生物科技有限公司 | Natural repair factor capable of effectively repairing and regenerating, preparation method and application thereof |
| KR20180041107A (en) * | 2018-04-16 | 2018-04-23 | 주식회사 엘지생활건강 | Composition for improving skin |
| KR102013164B1 (en) * | 2018-04-16 | 2019-08-22 | 주식회사 엘지생활건강 | Composition for improving skin |
| JP2022161273A (en) * | 2021-04-08 | 2022-10-21 | 丸善製薬株式会社 | Epidermal keratinocyte growth stimulator and transglutaminase-1 mrna expression promoter |
| JP2023075558A (en) * | 2021-11-19 | 2023-05-31 | 日本メナード化粧品株式会社 | Transglutaminase I production promoter and involucrin production promoter |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008007411A (en) | Transglutaminase production promoter and epidermal keratinization-normalizing agent | |
| JP2008007412A (en) | Involucrin production promoter and epidermal keratinization-normalizing agent | |
| JP2009084216A (en) | Atp production promoter and epidermal cell activator | |
| JP4768238B2 (en) | Profilagrin mRNA expression promoter | |
| CN102458355A (en) | Extracts of whole seeds of Moringa species and their use in cosmetic and/or dermatological compositions | |
| JP5860579B2 (en) | Filaggrin production promoter, involucrin production promoter, and transglutaminase-1 production promoter | |
| KR20160125784A (en) | Shiunko fermented oil and producing method thereof | |
| JP2009040757A (en) | Agent promoting laminin 5 production, agent normalizing dermal basement membrane, and agent promoting recovery of skin lesion | |
| JP2009256271A (en) | AQUAPORIN 3 mRNA EXPRESSION PROMOTOR AND SKIN MOISTURE RETENTION FUNCTION-IMPROVING AGENT | |
| JP2008184440A (en) | Skin external preparation for improving UV cell damage | |
| JP2009191039A (en) | EXPRESSION PROMOTOR FOR HYALURONIC ACID SYNTHETASE 3mRNA, EXPRESSION PROMOTOR FOR AQUAPORIN 3mRNA, EXPRESSION PROMOTOR FOR SERINE PALMITOYLTRANSFERASE mRNA, AND PRODUCTION PROMOTOR FOR LAMININ 5 | |
| KR102866606B1 (en) | Method of Producing Plant Extracts with Enhanced Physiological Activities, and Cosmetic Composition Containing Plant Extracts with Enhanced Physiological Activities | |
| KR20090070455A (en) | Cosmetic composition for preventing skin aging and improving skin wrinkles containing the extract of Licorice as an active ingredient using supercritical extraction | |
| JP2000119125A (en) | Skin aging prevention / improvement agent | |
| CN104523479A (en) | Application of prinsepiautilis Royle tender bud extractive to whitening product and whitening product | |
| FR2928549A1 (en) | USE OF AN EXTRACT OF BRASSOCATTLEYA MARCELLA KOSS ORCHIDEE AS AN AGENT TO PREVENT OR DELAY THE APPEARANCE OF SIGNS OF SKIN AGING | |
| JP2010065007A (en) | Claudin-1 production promoter and skin barrier function improving agent | |
| KR101974502B1 (en) | Cosmetic composition for anti-allergy and for improving atopic dermatitis comprising extract of anemone reflexa stephan as active ingredient | |
| JP7456720B2 (en) | Ceramide production promoter | |
| JP5164198B2 (en) | Profilaggrin production promoter, filaggrin production promoter and pore conspicuousness inhibitor | |
| JP2011068570A (en) | Laminin-5 production promoter, dermal basement membrane normalizing agent and skin damage recovery promoter | |
| JP2009114146A (en) | Transglutaminase-1 production promoter and involucrin production promoter | |
| KR102610940B1 (en) | Preparing method of cosmetic composition using skin cosmetic solution | |
| JP2009143833A (en) | Extract of crude drug and skin external preparation having the same as active ingredient | |
| KR101730166B1 (en) | Use in the cosmetics field of an extract of an exsudate of the plant Daniellia oliveri, in particular as an antiwrinkle agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090519 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20090519 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120314 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120514 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120801 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121001 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130306 |